{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T08:28:11Z","timestamp":1786609691985,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"PSI - Paul Scherrer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      The successful preclinical efficacy studies prompted a Phase I clinical trial to investigate [\n                      <jats:sup>161<\/jats:sup>\n                      Tb]Tb-SibuDAB. Deeper insight into potential undesired effects on normal tissues and organs remained to be investigated. The aim of this preclinical study was, therefore, to assess and compare the tolerability of [\n                      <jats:sup>161<\/jats:sup>\n                      Tb]Tb-SibuDAB with that of [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-SibuDAB, [\n                      <jats:sup>161<\/jats:sup>\n                      Tb]Tb-PSMA-I&amp;T and [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-I&amp;T.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The time-dependent tissue distribution profiles of [\n                      <jats:sup>161<\/jats:sup>\n                      Tb]Tb-SibuDAB and [\n                      <jats:sup>161<\/jats:sup>\n                      Tb]Tb-PSMA-I&amp;T were assessed in immunocompetent mice for dosimetry estimations. Substructural activity distribution in kidneys was further investigated ex vivo. In Study I, [\n                      <jats:sup>161<\/jats:sup>\n                      Tb]Tb-SibuDAB, [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-SibuDAB, [\n                      <jats:sup>161<\/jats:sup>\n                      Tb]Tb-PSMA-I&amp;T and [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-I&amp;T were administered at 30 MBq\/mouse while in Study II, additional activities of 15 MBq and 60 MBq [\n                      <jats:sup>161<\/jats:sup>\n                      Tb]Tb-SibuDAB were applied. Blood cell counts were determined on Days 10, 28 and 56 after radioligand injection while blood and bone marrow smears, blood plasma biomarkers and selected organs were investigated at study end on Day 56.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Organ uptake and absorbed doses were severalfold higher for SibuDAB than for PSMA-I&amp;T and terbium-161 delivered about 40% higher organ doses than lutetium-177. Kidney accumulation of radioligands was mainly localized in the renal cortex and blockable with excess ligand in the case of PSMA-I&amp;T but not for SibuDAB. In Study I, leukocyte and erythrocyte levels remained comparable between treated and control mice. Thrombocyte counts remained stable with PSMA-I&amp;T radioligands, while SibuDAB radioligands caused 23\u201328% decrease by Day 10, with full recovery seen for [\n                      <jats:sup>161<\/jats:sup>\n                      Tb]Tb-SibuDAB. In Study II, 60 MBq [\n                      <jats:sup>161<\/jats:sup>\n                      Tb]Tb-SibuDAB did not significantly reduce leukocyte levels, but erythrocyte counts were marginally lower on Days 10 and 28. Thrombocytes decreased to 18%, 23% and 44% of control values on Day 10 after application of 15 MBq, 30 MBq and 60 MBq, respectively. Thrombocyte counts recovered over time, although average values in some groups remained modestly decreased on Day 56. In both studies, blood plasma biomarkers were similar between treated and control groups. Histological assessment of bone marrow, spleen, liver and kidney showed only minimal alterations (score\u2009\u2264\u20091\/3).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Hematological changes were transient, but more pronounced after the application of SibuDAB than of PSMA-I&amp;T, most likely due to the prolonged blood circulation. Other organs and tissues remained unaffected by any of the applied treatments. Substituting lutetium-177 with terbium-161 did not significantly alter the measured parameters. It remains to be demonstrated clinically whether\n                      <jats:sup>161<\/jats:sup>\n                      Tb-based radioligands can be administered at activity levels comparable to their\n                      <jats:sup>177<\/jats:sup>\n                      Lu-based analogues.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-08129-1","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T07:40:05Z","timestamp":1786606805000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tolerability of [161Tb]Tb-SibuDAB in comparison to other PSMA-targeting radioligands in the preclinical setting"],"prefix":"10.1007","author":[{"given":"Korbinian","family":"Krieger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Katrina","family":"Mapanao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bolcaen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristel","family":"Kegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bernhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas P.","family":"van der Meulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulli","family":"K\u00f6ster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alin","family":"Chirindel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume P.","family":"Nicolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Schibli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9357-9688","authenticated-orcid":false,"given":"Cristina","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"8129_CR1","doi-asserted-by":"publisher","unstructured":"Hennrich U, Eder M. [177Lu]Lu-PSMA-617 (Pluvicto\u2122): The first FDA-approved radiotherapeutical for treatment of prostate cancer. Pharmaceuticals (Basel). 2022;15. https:\/\/doi.org\/10.3390\/ph15101292.","DOI":"10.3390\/ph15101292"},{"key":"8129_CR2","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","volume":"50","author":"C Kratochwil","year":"2023","unstructured":"Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, et al. Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023;50:2830\u201345. https:\/\/doi.org\/10.1007\/s00259-023-06255-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8129_CR3","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103. . https:\/\/doi.org\/10.1056\/NEJMoa2107322","journal-title":"N Engl J Med"},{"key":"8129_CR4","doi-asserted-by":"publisher","first-page":"857","DOI":"10.2967\/jnumed.119.236414","volume":"61","author":"J Violet","year":"2020","unstructured":"Violet J, Sandhu S, Iravani A, Ferdinandus J, Thang SP, Kong G, et al. Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center Phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer. J Nucl Med. 2020;61:857\u201365. https:\/\/doi.org\/10.2967\/jnumed.119.236414.","journal-title":"J Nucl Med"},{"key":"8129_CR5","doi-asserted-by":"publisher","unstructured":"Bernhardt P, Svensson J, Hemmingsson J, van der Meulen NP, Zeevaart JR, Konijnenberg MW, et al. Dosimetric analysis of the short-ranged particle emitter 161Tb for radionuclide therapy of metastatic prostate cancer. Cancers (Basel). 2021;13. https:\/\/doi.org\/10.3390\/cancers13092011.","DOI":"10.3390\/cancers13092011"},{"key":"8129_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40658-020-00301-2","volume":"7","author":"ME Alcocer-Avila","year":"2020","unstructured":"Alcocer-Avila ME, Ferreira A, Quinto MA, Morgat C, Hindie E, Champion C. Radiation doses from 161Tb and 177Lu in single tumour cells and micrometastases. EJNMMI Phys. 2020;7:33. https:\/\/doi.org\/10.1186\/s40658-020-00301-2.","journal-title":"EJNMMI Phys"},{"key":"8129_CR7","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.2967\/jnumed.123.265509","volume":"64","author":"A Larouze","year":"2023","unstructured":"Larouze A, Alcocer-Avila M, Morgat C, Champion C, Hindie E. Membrane and nuclear absorbed doses from 177Lu and 161Tb in tumor clusters: effect of cellular heterogeneity and potential benefit of dual targeting-a Monte Carlo study. J Nucl Med. 2023;64:1619\u201324. https:\/\/doi.org\/10.2967\/jnumed.123.265509.","journal-title":"J Nucl Med"},{"key":"8129_CR8","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s00259-019-04345-0","volume":"46","author":"C M\u00fcller","year":"2019","unstructured":"M\u00fcller C, Umbricht CA, Gracheva N, Tschan VJ, Pellegrini G, Bernhardt P, et al. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1919\u201330. https:\/\/doi.org\/10.1007\/s00259-019-04345-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8129_CR9","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.2967\/jnumed.123.265524","volume":"64","author":"VJ Tschan","year":"2023","unstructured":"Tschan VJ, Busslinger SD, Bernhardt P, Grundler PV, Zeevaart JR, K\u00f6ster U, et al. Albumin-binding and conventional PSMA ligands in combination with 161Tb: biodistribution, dosimetry, and preclinical therapy. J Nucl Med. 2023;64:1625\u201331. https:\/\/doi.org\/10.2967\/jnumed.123.265524.","journal-title":"J Nucl Med"},{"key":"8129_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13550-016-0171-1","volume":"6","author":"S Haller","year":"2016","unstructured":"Haller S, Pellegrini G, Vermeulen C, van der Meulen NP, K\u00f6ster U, Bernhardt P, et al. Contribution of Auger\/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of 161Tb-folate and 177Lu-folate. EJNMMI Res. 2016;6:13. https:\/\/doi.org\/10.1186\/s13550-016-0171-1.","journal-title":"EJNMMI Res"},{"key":"8129_CR11","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1007\/s00259-024-06827-2","volume":"51","author":"SD Busslinger","year":"2024","unstructured":"Busslinger SD, Mapanao AK, Kegler K, Bernhardt P, Fl\u00fchmann F, Fricke J, et al. Comparison of the tolerability of 161Tb- and 177Lu-labeled somatostatin analogues in the preclinical setting. Eur J Nucl Med Mol Imaging. 2024;51:4049\u201361. https:\/\/doi.org\/10.1007\/s00259-024-06827-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8129_CR12","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/RLU.0000000000004589","volume":"48","author":"F Rosar","year":"2023","unstructured":"Rosar F, Maus S, Schaefer-Schuler A, Burgard C, Khreish F, Ezziddin S. New horizons in radioligand therapy: 161Tb-PSMA-617 in advanced mCRPC. Clin Nucl Med. 2023;48:433\u20134. https:\/\/doi.org\/10.1097\/RLU.0000000000004589.","journal-title":"Clin Nucl Med"},{"key":"8129_CR13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265291","author":"A Al-Ibraheem","year":"2023","unstructured":"Al-Ibraheem A, Doudeen RM, Juaidi D, Abufara A, Maus S. 161Tb-PSMA radioligand therapy: first-in-human SPECT\/CT imaging. J Nucl Med. 2023. https:\/\/doi.org\/10.2967\/jnumed.122.265291.","journal-title":"J Nucl Med"},{"key":"8129_CR14","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.7150\/thno.92273","volume":"14","author":"A Schaefer-Schuler","year":"2024","unstructured":"Schaefer-Schuler A, Burgard C, Blickle A, Maus S, Petrescu C, Petto S, et al. [161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [177Lu]Lu-PSMA-617. Theranostics. 2024;14:1829\u201340. https:\/\/doi.org\/10.7150\/thno.92273.","journal-title":"Theranostics"},{"key":"8129_CR15","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.2967\/jnumed.124.267650","volume":"65","author":"JP Buteau","year":"2024","unstructured":"Buteau JP, Kostos L, Alipour R, Jackson P, McInstosh L, Emmerson B, et al. Clinical trial protocol for VIOLET: a single-center, Phase I\/II trial evaluation of radioligand treatment in patients with metastatic castration-resistant prostate cancer with [161Tb]Tb-PSMA-I&T. J Nucl Med. 2024;65:1231\u20138. https:\/\/doi.org\/10.2967\/jnumed.124.267650.","journal-title":"J Nucl Med"},{"key":"8129_CR16","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(25)00332-8","volume":"26","author":"JP Buteau","year":"2025","unstructured":"Buteau JP, Kostos L, Jackson PA, Xie J, Haskali MB, Alipour R, et al. First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1\/2 study. Lancet Oncol. 2025;26:1009\u201317. https:\/\/doi.org\/10.1016\/S1470-2045(25)00332-8.","journal-title":"Lancet Oncol"},{"key":"8129_CR17","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1021\/acs.molpharmaceut.7b00877","volume":"15","author":"M Benesova","year":"2018","unstructured":"Benesova M, Umbricht CA, Schibli R, M\u00fcller C. Albumin-binding PSMA ligands: optimization of the tissue distribution profile. Mol Pharm. 2018;15:934\u201346. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00877.","journal-title":"Mol Pharm"},{"key":"8129_CR18","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1021\/acs.molpharmaceut.8b00152","volume":"15","author":"CA Umbricht","year":"2018","unstructured":"Umbricht CA, Benesova M, Schibli R, M\u00fcller C. Preclinical development of novel PSMA-targeting radioligands: modulation of albumin-binding properties to improve prostate cancer therapy. Mol Pharm. 2018;15:2297\u2013306. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00152.","journal-title":"Mol Pharm"},{"key":"8129_CR19","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.7150\/thno.40482","volume":"10","author":"LM Deberle","year":"2020","unstructured":"Deberle LM, Benesova M, Umbricht CA, Borgna F, B\u00fcchler M, Zhernosekov K, et al. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity. Theranostics. 2020;10:1678\u201393. https:\/\/doi.org\/10.7150\/thno.40482.","journal-title":"Theranostics"},{"key":"8129_CR20","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1021\/acs.molpharmaceut.1c00994","volume":"19","author":"F Borgna","year":"2022","unstructured":"Borgna F, Deberle LM, Busslinger SD, Tschan VJ, Walde LM, Becker AE, et al. Preclinical investigations to explore the difference between the diastereomers [177Lu]Lu-SibuDAB and [177Lu]Lu-RibuDAB toward prostate cancer therapy. Mol Pharm. 2022;19:2105\u201314. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00994.","journal-title":"Mol Pharm"},{"key":"8129_CR21","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1007\/s00259-025-07102-8","volume":"52","author":"P Ritt","year":"2025","unstructured":"Ritt P, Fernandez R, Soza-Ried C, Nicolai H, Amaral H, Krieger K, et al. Biodistribution and dosimetry of [177Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2025;52:2431\u201343. https:\/\/doi.org\/10.1007\/s00259-025-07102-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8129_CR22","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1007\/s00259-025-07634-z","volume":"53","author":"R Fernandez","year":"2026","unstructured":"Fernandez R, Soza-Ried C, Kramer V, Krieger K, M\u00fcller C, Qin Y, et al. Safety and efficacy of [177Lu]Lu-SibuDAB in patients with progressive metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2026;53:2282\u201394. https:\/\/doi.org\/10.1007\/s00259-025-07634-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8129_CR23","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1007\/s00259-024-07009-w","volume":"52","author":"A Chirindel","year":"2025","unstructured":"Chirindel A, Nicolas GP, Westerbergh F, McDougall L, Schmid DE, Geistlich S, et al. First-in-human administration of [161Tb]Tb-SibuDAB and comparative dosimetry with standard [177Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study. Eur J Nucl Med Mol Imaging. 2025;52:1628\u201330. https:\/\/doi.org\/10.1007\/s00259-024-07009-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8129_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s41181-019-0063-6","volume":"4","author":"N Gracheva","year":"2019","unstructured":"Gracheva N, M\u00fcller C, Talip Z, Heinitz S, K\u00f6ster U, Zeevaart JR, et al. Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapy. EJNMMI Radiopharm Chem. 2019;4:12. https:\/\/doi.org\/10.1186\/s41181-019-0063-6.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"8129_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7:27\u201331. https:\/\/doi.org\/10.4103\/0976-0105.177703.","journal-title":"J Basic Clin Pharm"},{"key":"8129_CR26","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1089\/cbr.2006.320","volume":"22","author":"E Larsson","year":"2007","unstructured":"Larsson E, Strand SE, Ljungberg M, Jonsson BA. Mouse S-factors based on Monte Carlo simulations in the anatomical realistic Moby phantom for internal dosimetry. Cancer Biother Radiopharm. 2007;22:438\u201342. https:\/\/doi.org\/10.1089\/cbr.2006.320.","journal-title":"Cancer Biother Radiopharm"},{"key":"8129_CR27","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","volume":"41","author":"F Faul","year":"2009","unstructured":"Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41:1149\u201360. . https:\/\/doi.org\/10.3758\/BRM.41.4.1149","journal-title":"Behav Res Methods"},{"key":"8129_CR28","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1515\/labmed-2012-0027","volume":"36","author":"T Binder","year":"2012","unstructured":"Binder T, Diem H, Fuchs R, Gutensohn K, Nebe T. Pappenheim stain: description of a hematological standard stain - history, chemistry, procedure, artifacts and problem solutions. J Lab Med. 2012;36:293\u2013309. https:\/\/doi.org\/10.1515\/labmed-2012-0027.","journal-title":"J Lab Med"},{"key":"8129_CR29","doi-asserted-by":"publisher","unstructured":"Busslinger SD, Tschan VJ, Richard OK, Talip Z, Schibli R, M\u00fcller C. [225Ac]Ac-SibuDAB for targeted alpha therapy of prostate cancer: preclinical evaluation and comparison with [225Ac]Ac-PSMA-617. Cancers (Basel). 2022;14. https:\/\/doi.org\/10.3390\/cancers14225651.","DOI":"10.3390\/cancers14225651"},{"key":"8129_CR30","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3390\/pharmaceutics14040731","volume":"14","author":"A Kristiansson","year":"2022","unstructured":"Kristiansson A, Vilhelmsson Timmermand O, Altai M, Strand J, Strand S-E, \u00c5kerstr\u00f6m B, et al. Hematological toxicity in mice after high activity injections of 177Lu-PSMA-617. Pharmaceutics. 2022;14:731.","journal-title":"Pharmaceutics"},{"key":"8129_CR31","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.2967\/jnumed.117.193359","volume":"58","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Stuparu AD, Evans-Axelsson S, Luckerath K, Wei L, Kim W, et al. Establishing 177Lu-PSMA-617 radioligand therapy in a syngeneic model of murine prostate cancer. J Nucl Med. 2017;58:1786\u201392. https:\/\/doi.org\/10.2967\/jnumed.117.193359.","journal-title":"J Nucl Med"},{"key":"8129_CR32","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1007\/s00259-022-05837-2","volume":"49","author":"VJ Tschan","year":"2022","unstructured":"Tschan VJ, Borgna F, Busslinger SD, Stirn M, Rodriguez JMM, Bernhardt P, et al. Preclinical investigations using [177Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer. Eur J Nucl Med Mol Imaging. 2022;49:3639\u201350. https:\/\/doi.org\/10.1007\/s00259-022-05837-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8129_CR33","first-page":"96","volume":"65","author":"KE O\u2019Connell","year":"2015","unstructured":"O\u2019Connell KE, Mikkola AM, Stepanek AM, Vernet A, Hall CD, Sun CC, et al. Practical murine hematopathology: a comparative review and implications for research. Comp Med. 2015;65:96\u2013113.","journal-title":"Comp Med"},{"key":"8129_CR34","doi-asserted-by":"publisher","first-page":"9019","DOI":"10.7150\/thno.115831","volume":"15","author":"F Rosar","year":"2025","unstructured":"Rosar F, Burgard C, Petrescu C, Blickle A, Bartholoma M, Maus S, et al. Pilot experience of [161Tb]Tb-PSMA-617 RLT in mCRPC patients after conventional PSMA RLT within a prospective registry. Theranostics. 2025;15:9019\u201328. https:\/\/doi.org\/10.7150\/thno.115831.","journal-title":"Theranostics"},{"key":"8129_CR35","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s00259-020-05057-6","volume":"48","author":"EAM Ruigrok","year":"2021","unstructured":"Ruigrok EAM, van Vliet N, Dalm SU, de Blois E, van Gent DC, Haeck J, et al. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. Eur J Nucl Med Mol Imaging. 2021;48:1339\u201350. https:\/\/doi.org\/10.1007\/s00259-020-05057-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8129_CR36","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2967\/jnumed.121.262713","volume":"63","author":"C Schuchardt","year":"2022","unstructured":"Schuchardt C, Zhang J, Kulkarni HR, Chen X, Muller D, Baum RP. Prostate-Specific membrane antigen radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution, and dosimetry. J Nucl Med. 2022;63:1199\u2013207. https:\/\/doi.org\/10.2967\/jnumed.121.262713.","journal-title":"J Nucl Med"},{"key":"8129_CR37","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267452","author":"Z Ells","year":"2024","unstructured":"Ells Z, Grogan TR, Czernin J, Dahlbom M, Calais J. Dosimetry of [177Lu]Lu-PSMA-targeted radiopharmaceutical therapies in patients with prostate cancer: A comparative systematic review and metaanalysis. J Nucl Med. 2024. https:\/\/doi.org\/10.2967\/jnumed.124.267452.","journal-title":"J Nucl Med"},{"key":"8129_CR38","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13550-014-0063-1","volume":"4","author":"M Weineisen","year":"2014","unstructured":"Weineisen M, Simecek J, Schottelius M, Schwaiger M, Wester HJ. Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Res. 2014;4:63. https:\/\/doi.org\/10.1186\/s13550-014-0063-1.","journal-title":"EJNMMI Res"},{"key":"8129_CR39","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.271864","author":"M Andersson","year":"2026","unstructured":"Andersson M, Opsomer T, Saldarriaga Vargas C. Nephron-level dosimetry reveals increased absorbed dose heterogeneity of 161Tb- versus 177Lu-DOTATATE in murine kidneys despite similar pharmacokinetics. J Nucl Med. 2026. https:\/\/doi.org\/10.2967\/jnumed.125.271864.","journal-title":"J Nucl Med"},{"key":"8129_CR40","doi-asserted-by":"publisher","unstructured":"de Roode KE, Joosten L, Behe M. Towards the magic radioactive bullet: improving targeted radionuclide therapy by reducing the renal retention of radioligands. Pharmaceuticals (Basel). 2024;17. https:\/\/doi.org\/10.3390\/ph17020256.","DOI":"10.3390\/ph17020256"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08129-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08129-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08129-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T07:40:05Z","timestamp":1786606805000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08129-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":40,"alternative-id":["8129"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08129-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"7 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in agreement with the national law and PSI-internal guidelines of radiation safety protection. In vivo experiments were approved by the local veterinary department and ethics committee and conducted in accordance with the Swiss law of animal protection (License N\u00b0 75668).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The following is a competing financial interest: Patent applications on albumin-binding PSMA ligands have been filed by ITM Isotope Technologies Munich SE, Germany, in which R. Schibli and C. M\u00fcller are listed as co-inventors. The study was also supported by ITM Isotope Technologies Munich SE, Germany.","order":4,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}